Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

 

PART I

 

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

 

A.Directors and senior management

 

Not applicable.

 

B.Advisers

 

Not applicable.

 

C.Auditors

 

Not applicable.

 

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE

 

A.Offer statistics

 

Not applicable.

 

B.Method and expected timetable

 

Not applicable.

 

ITEM 3. KEY INFORMATION

 

A.Selected Financial Data

 

We have derived the selected statements of comprehensive loss for the years ended December 31, 2018, 2017 and 2016 presented below and the selected balance sheet data as of December 31, 2018 and 2017 presented below from our audited financial statements included elsewhere in this Annual Report on Form 20-F. The selected statement of comprehensive income for the years ended December 31, 2015 and 2014 and the selected balance sheet data as of December 31, 2016, 2015 and 2014 have been derived from our audited financial statements not included in this Annual Report on Form 20-F.

 

Our historical results are not necessarily indicative of the results that may be expected in the future. The following summary financial data should be read in conjunction with “Item 5. Operating and Financial Review and Prospects” and our financial statements included elsewhere in this Annual Report.

 

We maintain our books and records and our audited financial statements in Swiss Francs (CHF).

 

 

For the Years Ended December 31,

(in CHF thousands)

2018

2017

2016

2015

2014
Income Statement Data:          
Contract revenue 7,194 20,255 23,214 39,090 30,269
Research and development expenses (44,277) (32,663) (25,774) (17,049) (16,116)
General and administrative expenses (12,467) (10,131) (7,896) (3,417) (3,436)
Operating income / (loss) (49,550) (22,539) (10,456) 18,624 10,717
Finance result—net (1,401) (3,872) 3,360 1,646 27
           
Net income / (loss) before tax (50,951) (26,411) (7,096) 20,270 10,744
Income taxes — 
Net income / (loss) for the period (50,951) (26,411) (7,096) 20,270 10,744

 

 3


© AC Immune 2015